KALA BIO to Present at TD Cowen 44th Annual Healthcare Conference
ARLINGTON, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research,...
Pharmaceutical
PMV Pharmaceuticals to Participate in the TD Cowen 44th Annual Health Care Conference
PRINCETON, N.J., Feb. 26, 2024 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery...
Avadel Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full Year 2023 Financial Results on March 4
DUBLIN, Ireland, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines...
Biora Therapeutics Announces Successful Completion of Single-Ascending Dose (SAD) Cohorts of Phase 1 Clinical Study of BT-600
Data expected to be shared during March corporate update With SAD cohorts complete, MAD cohorts to begin dosing in March...
BeyondSpring Regains Compliance with Nasdaq Minimum Bid Price and Periodic Filing Requirements
FLORHAM PARK, N.J., Feb. 26, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a global clinical-stage...
Matinas BioPharma Provides Positive Outcomes Update on the MAT2203 Compassionate/Expanded Use Access Program, Including Multiple Patients with Complete Clinical Resolution
A total of 19 patients with serious/life-threatening invasive fungal infections have been enrolled, including aspergillosis, mucormycosis, fusarium, candidiasis, cryptococcosis, and...
Saxony-Anhalt Embraces Change as an Opportunity: Billions Invested in Key Transformation Industries
Companies are currently injecting nearly three billion euros into projects in Saxony-Anhalt, marking a significant commitment to transformative initiatives. When...
MindBio Therapeutics Announces Positive Depression Data from World-First Phase 2a Take-Home Microdosing Trial
MindBio demonstrates safe, effective take home use of MB22001 in Depressed patients over an 8-week, world first take-home trialRapid, robust,...
Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®
SIMLANDI is the first citrate-free, high-concentration biosimilar to be designated interchangeable to Humira in the U.S. SIMLANDI is the first...
Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®
SIMLANDI is the first citrate-free, high-concentration biosimilar to be designated interchangeable to Humira in the U.S. SIMLANDI is the first...
Biofrontera Inc. Announces Closing of Private Placement of up to $16.0 Million Priced at Market per Nasdaq Rules
Company closed financing of $8.0 million with an additional $8.0 million second tranche tied to milestones for aggregate proceeds of...
Jaguar Health Requests and Receives Hearing on Nasdaq Listing Compliance
SAN FRANCISCO, CA / ACCESSWIRE / February 23, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today provided...
NLS Pharmaceutics Submits Plan to Regain Listing Compliance With Nasdaq
ZÜRICH, SWITZERLAND / ACCESSWIRE / February 23, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage...
iZafe Group Launches Dosell Version 3.0 and Moves Production
STOCKHOLM, SWEDEN / ACCESSWIRE / February 23, 2024 / iZafe Group (STO:IZAFE-B.ST) iZafe Group AB ("iZafe Group") is pleased to...
FDA Moves Ahead With MMJ Cannabis Drug Application
"MMJ International Holdings has manufactured a botanical extract in a final dose form gel cap and will investigate its novel...
Bausch Health Announces Fourth-Quarter and Full-Year 2023 Results
Fourth-Quarter revenues of $2.41 billion, up 10% on a Reported basis and up 4% on an Organic 1 basisFull-Year revenues...
Dr. Robert Huizinga Elected to the Kane Biotech Board and Appointed Executive Chair
WINNIPEG, Manitoba, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company” or “Kane Biotech” or “Kane”)...
Lisata Therapeutics to Host Year-End 2023 Conference Call on Thursday, February 29, 2024 at 4:30 p.m. Eastern Time
BASKING RIDGE, N.J., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage...
Soleno Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference
REDWOOD CITY, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing...
Tarsus Announces Positive Topline Results from Carpo, a Phase 2a Proof-of-Concept “Tick-Kill” Trial Evaluating TP-05 (lotilaner) for the Prevention of Lyme Disease
TP-05 demonstrated tolerability and statistically significant tick mortality, suggesting potential for on-demand Lyme disease prophylaxisIRVINE, Calif., Feb. 22, 2024 (GLOBE...